CJC-1295 and pregnancy: what the safety data actually says

Last updated 2026-07-30

Is CJC-1295 safe to use during pregnancy?

No. There is no human safety data on CJC-1295 in pregnancy, and nothing published on lactation exposure either. CJC-1295 is sold in the United States as a research chemical, not an approved drug, and every legitimate supplier's certificate of analysis says "not for human consumption." That labeling exists because CJC-1295 has never gone through an FDA new drug application process, which is the only mechanism that generates the kind of controlled pregnancy exposure data you'd want before making a safety claim ^[1]. The absence of data is not the same as evidence of safety. It's the opposite problem: nobody has looked, so nobody can tell you what happens. Growth hormone releasing hormone (GHRH) analogues like CJC-1295 work by stimulating the pituitary to release more growth hormone, which then drives IGF-1 production in the liver and elsewhere ^[2]. Both GH and IGF-1 pathways are deeply involved in normal fetal growth, placental development, and glucose handling in pregnancy. Manipulating that axis with an unapproved, unmonitored compound during pregnancy is not a small variable to tinker with. If you are pregnant, trying to conceive, or breastfeeding, the only defensible position is to not use CJC-1295, ipamorelin, or any other GH secretagogue until you've talked to your OB or a physician who knows your full history.

What does the animal research on GHRH analogues actually show?

The preclinical package behind CJC-1295 is thin and old, mostly consisting of pharmacokinetic and receptor-binding work in rodents and primates published in the mid-2000s, not reproductive toxicology studies designed to answer pregnancy questions ^[3]. The original modified GRF(1-29) analogue work by Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism (2006) tested single and multiple dosing in healthy adult men and women, not pregnant subjects, and did not include reproductive or teratogenicity endpoints ^[3]. Standard reproductive toxicology testing for a drug candidate involves dedicated studies: fertility and early embryonic development studies, embryo-fetal development studies across at least two species, and pre/postnatal development studies, following frameworks like the ICH S5 guidance that FDA and international regulators expect before a drug is deemed acceptable in pregnancy-relevant populations ^[4]. None of that formal battery exists in the public record for CJC-1295. So when someone tells you "it's fine, it's just GHRH" or points to endogenous GHRH physiology as reassurance, that's a leap. Native GHRH is a normal part of human physiology at a very tightly regulated pulsatile dose. CJC-1295 is a modified molecule, engineered specifically to resist enzymatic degradation and extend half-life (more on that below), which changes the exposure profile in ways that haven't been mapped in pregnancy.

Why can't I just compare this to approved growth hormone drugs like Genotropin?

Because approved recombinant human growth hormone (rhGH) products like somatropin have their own pregnancy labeling, and it is not reassuring in the way people assume. Genotropin's FDA label states growth hormone "is not recommended for use in patients with acute critical illness" and separately notes there are no adequate, well-controlled studies of somatropin in pregnant women, so use in pregnancy is generally reserved for cases where the anticipated benefit justifies the potential risk ^[5]. That's for an FDA-approved, decades-old, real prescription drug with actual manufacturing quality control and a full label. CJC-1295 has none of that regulatory scaffolding. If the approved version of "more growth hormone" carries an unresolved pregnancy safety question, an unapproved, unregulated GHRH analogue with no dedicated pregnancy studies at all is not a safer bet, it's a bigger unknown. There's also a practical sourcing reality: legitimate research-use suppliers, including the ones reviewed on this site, sell CJC-1295 explicitly as a research chemical for laboratory use, not for human administration under any circumstance, pregnant or not ^[1]. That labeling isn't a technicality to route around. It reflects the actual state of the evidence.

CJC-1295 with DAC vs without DAC: does the difference matter for pregnancy risk?

It matters for exposure duration, which matters for risk exposure math, even though neither version has pregnancy data. CJC-1295 without DAC (also sold as "CJC-1295 no DAC" or under the peptide name mod GRF 1-29) has a short half-life, on the order of 30 minutes in circulation, so it acts more like a pulse and clears quickly ^[3]. CJC-1295 with DAC (Drug Affinity Complex) is chemically modified to bind to serum albumin, which extends its half-life to roughly 6 to 8 days based on the Teichman 2006 pharmacokinetic data, giving sustained, non-pulsatile elevation of GH and IGF-1 over that whole window ^[3]. That distinction matters practically: if someone unknowingly conceives while using CJC-1295 with DAC, the compound and its downstream GH/IGF-1 effects don't clear out over a day or two, they persist for over a week per dose, compounding with each subsequent injection if dosing continues. There is no study quantifying what that sustained exposure does to early embryonic development, implantation, or first-trimester organogenesis. That's not a small gap to wave away, and it's a big part of why stopping immediately upon a positive pregnancy test (or upon actively trying to conceive) is the only responsible move regardless of which version someone has been using. For readers comparing the two versions for other reasons, the cjc-1295 pros and cons page covers the DAC/no-DAC tradeoff for dosing frequency and side effect profile outside of pregnancy contexts.

What about ipamorelin, is that any safer to combine or use alone during pregnancy?

No, the same reasoning applies to ipamorelin, and the combination doesn't average out to a safer profile. Ipamorelin is a growth hormone releasing peptide (GHRP), a ghrelin receptor agonist, and it is commonly paired with CJC-1295 because the two act on different receptors (GHRH receptor vs. ghrelin/GHS receptor) to produce a larger combined GH pulse than either alone in small mechanistic studies ^[6]. That rationale is about additive GH release in adults, it says nothing about fetal safety, and no pregnancy or reproductive toxicology data exists for ipamorelin either. Stacking two unapproved secretagogues doesn't cancel out unknowns, it adds a second uncharacterized variable to a first one. If you're currently on both and think you might be pregnant, stop both and get a pregnancy test and medical guidance, don't try to figure out which one is "more risky" to keep.

Could CJC-1295 affect fertility or the ability to conceive?

There's no direct human fertility-trial data on CJC-1295 itself, but growth hormone and IGF-1 both interact with reproductive hormone axes in ways documented outside the peptide research world. In women, growth hormone has a recognized supportive role in ovarian follicular response, which is why some fertility clinics use adjunct rhGH (an approved drug, under monitoring) in select IVF protocols for poor responders, a use reviewed in fertility literature but still considered adjunctive and not universally beneficial ^[7]. That's a controlled clinical use of an approved drug in a monitored setting, a completely different situation from self-administered CJC-1295 with no monitoring and no established dose-response safety data. What this means practically: growth hormone axis manipulation is not reproductively neutral. It's plausible it could influence cycle regularity or ovarian response in some way, positive, negative, or null, and nobody has run the actual studies on CJC-1295 to say which. If you're actively trying to conceive, the honest move is to stop CJC-1295 and ipamorelin beforehand and let your natural GH pulsatility (which is already substantial in reproductive-age adults) do its normal job.

What should I do if I got pregnant while using CJC-1295 or ipamorelin?

Stop the peptide immediately and call your OB or midwife, and tell them exactly what you were using, including brand, dose, and how long. This isn't a moment for embarrassment or minimizing; your provider needs the real timeline to make any informed monitoring decisions, and honest peptide use disclosure is a normal part of prenatal intake, not a confession. There's no antidote or reversal protocol, and no clinical pathway for "peptide exposure monitoring" the way there is for, say, known teratogen exposure protocols (like isotretinoin's iPLEDGE program). Your provider will most likely rely on standard early pregnancy monitoring (dating ultrasound, standard first-trimester screening) rather than any CJC-1295-specific test, because no such test or established risk threshold exists. Don't try to self-manage this by searching bodybuilding forums for what other users did. Peptide forums are not a substitute for a clinician who knows your actual pregnancy and history, and anecdotal "I used it and my baby was fine" reports (survivorship bias, not evidence) are exactly the kind of folklore this topic gets buried in.

Is CJC-1295 safe while breastfeeding?

There's no lactation transfer data for CJC-1295, meaning nobody has measured whether it passes into breast milk or at what concentration, so the honest answer is that safety during breastfeeding is unknown, not confirmed either way. Given that CJC-1295 with DAC persists in serum for roughly a week per dose ^[3], any transfer into milk would likely be sustained rather than a brief one-time blip, which is a meaningfully different risk profile than a drug that clears in hours. Compare that again to approved rhGH: even Genotropin's label notes caution is recommended when administering to a nursing mother, without a clean answer either, because rhGH lactation data is itself limited ^[5]. If the FDA-approved comparator drug can't give a firm reassurance, an unregulated research compound with zero lactation studies certainly can't. The straightforward answer for breastfeeding parents is to avoid CJC-1295 and ipamorelin during that window too.

Why is there no real pregnancy safety data on CJC-1295 in the first place?

Because CJC-1295 has never been submitted through an FDA drug approval pathway, and pregnancy safety data is generated almost exclusively through that regulatory process, not through independent academic curiosity. Getting a drug to the point where regulators or researchers systematically study pregnancy exposure requires it to first clear Phase 1 to Phase 3 trials in non-pregnant populations, and CJC-1295's public trial record stops at that early Teichman 2006 pharmacokinetic and short-term dosing study in healthy adults ^[3]. It never advanced to an approved product with post-marketing pregnancy registries, the kind of long-term data source that FDA-approved drugs eventually accumulate. That's the structural reason bodybuilding and longevity forums are full of confident claims about CJC-1295 and pregnancy while PubMed has essentially nothing. Forum confidence fills a vacuum that clinical trials would otherwise occupy. If you're evaluating other CJC-1295 claims you've read online, the same evidence gap shows up across the board, which is why it's worth checking sources against something like the cjc-1295 reviews roundup or the cjc-1295 success rate page before trusting a forum thread's framing of "safe" or "proven."

How does this compare to other things people avoid during pregnancy for similar reasons?

What should someone planning pregnancy do if they're currently using CJC-1295 for other goals?

Stop it before you start trying, ideally with enough lead time to let your body return to baseline GH pulsatility, and talk to your prescriber or OB about timing if you're on a structured protocol. Because CJC-1295 with DAC has a multi-day half-life and no established clearance-to-safety data, there isn't a clean "stop X weeks before conception" number anyone can give you with confidence; that number simply hasn't been studied ^[3]. A reasonable, conservative approach some clinicians and informed users apply to unstudied research compounds generally is to stop at least one full menstrual cycle (roughly 4 to 6 weeks) before actively trying, giving several DAC half-lives to clear and giving natural cycle-based hormone patterns time to normalize, though this is a precautionary buffer, not a number backed by a specific CJC-1295 pregnancy study. If you were mid-protocol and are now trying to conceive, this is also a good moment to reassess whether the original goal (often body composition or general anti-aging interest) justified continued use at all; the is cjc-1295 worth it analysis and cjc-1295 before and after results discussion are useful context for that broader cost-benefit conversation, separate from the pregnancy question entirely.

Where can I find a properly sourced, provider-reviewed research option if I still want to explore CJC-1295 outside of pregnancy?

If you've read all of the above and it doesn't apply to you (you're not pregnant, not breastfeeding, not trying to conceive), sourcing quality still matters enormously for any other safety question you're weighing. CJC-1295 Co reviews providers who work with licensed compounding pharmacy partners and physician oversight rather than pointing people toward anonymous online vendors with no chain of accountability. That provider-reviewed route doesn't create pregnancy safety data that doesn't exist, no legitimate provider will claim otherwise, but it does mean a licensed pharmacist and prescribing clinician are in the loop on your full health picture, including asking about pregnancy status and plans, which is exactly the kind of check an anonymous research-chemical listing never asks you.

What's the single most important takeaway for someone researching CJC-1295 and pregnancy?

There is no human pregnancy or lactation data on CJC-1295 or ipamorelin, both are sold explicitly as research chemicals not intended for human use, and the closest regulatory comparator (approved rhGH) still carries its own unresolved pregnancy caution on the label ^[1][5]. The DAC version's week-long half-life makes accidental exposure during early pregnancy a longer, more sustained event than the no-DAC version's 30-minute clearance, which is one more reason to stop immediately and disclose use to your provider rather than wait it out ^[3]. None of the mechanistic rationale for stacking CJC-1295 with ipamorelin, or for choosing DAC over no-DAC, changes any of this. If you are pregnant, breastfeeding, or trying to conceive, stop both compounds and let a physician who knows your history make the next call.

Frequently asked questions

Can CJC-1295 cause a miscarriage?

There's no human study establishing or ruling out a miscarriage link. Growth hormone and IGF-1 pathways are active in early placental and embryonic development, and manipulating them with an unstudied, unapproved compound is a real theoretical concern, but no data set exists that confirms CJC-1295 specifically causes or doesn't cause miscarriage.

Is ipamorelin safer than CJC-1295 during pregnancy?

No. Neither has any human pregnancy data. Ipamorelin works through a different receptor (ghrelin/GHS-R) than CJC-1295's GHRH receptor pathway, but that mechanistic difference doesn't translate into any known pregnancy safety advantage for either compound.

How long does CJC-1295 stay in your system if you're worried about early pregnancy exposure?

No-DAC CJC-1295 has a half-life around 30 minutes and clears within hours. CJC-1295 with DAC binds serum albumin and has a half-life of roughly 6 to 8 days per pharmacokinetic data from Teichman et al. (2006), so it persists far longer per dose.

Does CJC-1295 affect fertility or the ability to get pregnant?

No CJC-1295-specific fertility trial exists. Growth hormone does interact with ovarian follicular response, and adjunct approved rhGH is used in some monitored IVF protocols for poor responders, but that's a different, clinically supervised context from self-administered CJC-1295 with no monitoring.

Can I use CJC-1295 while trying to conceive?

It's not recommended. Because there's no established clearance-to-safety timeline, a conservative approach some take with unstudied research compounds is stopping at least one full menstrual cycle before actively trying, though this buffer is precautionary, not backed by a CJC-1295-specific study.

Is CJC-1295 approved by the FDA for any use, including pregnancy?

No. CJC-1295 has never received FDA approval for any indication. It's sold by research suppliers labeled "not for human consumption," which is a materially different regulatory status than an approved prescription drug with a pregnancy-specific label section.

What does the CJC-1295 with DAC vs no DAC difference mean for someone worried about pregnancy exposure?

DAC extends half-life to roughly 6 to 8 days versus about 30 minutes for no-DAC, per the original Teichman 2006 pharmacokinetic study. That means accidental exposure during early pregnancy is a longer, more sustained event with the DAC version.

Should I tell my OB if I used CJC-1295 before finding out I was pregnant?

Yes, tell them the full details: which compound, dose, and duration. There's no CJC-1295-specific monitoring protocol, so your provider will likely rely on standard early pregnancy monitoring, but accurate disclosure helps them make informed decisions about your care.

Is CJC-1295 safe while breastfeeding?

Unknown, not confirmed safe. No lactation transfer studies exist for CJC-1295. Given its multi-day half-life in the DAC form, any transfer into breast milk would likely be sustained rather than brief, which is a reasonable basis for avoiding it during breastfeeding.

Does the FDA-approved growth hormone drug Genotropin have pregnancy warnings, and does that tell us anything about CJC-1295?

Yes, Genotropin's label notes there are no adequate, well-controlled studies in pregnant women and recommends use only if benefit outweighs risk. If the approved, well-studied version carries that caution, an unapproved, unstudied compound like CJC-1295 warrants at least equal caution.

Why is there so little scientific data on CJC-1295 and pregnancy compared to other drugs?

CJC-1295 never advanced through FDA drug trial phases into an approved product, and pregnancy safety data is generated almost exclusively through that regulatory pipeline and post-marketing registries. Its public research record stops at early pharmacokinetic studies in non-pregnant adults from 2006.

Are there any circumstances where a doctor would prescribe CJC-1295 during pregnancy?

No. CJC-1295 is not an approved prescription drug in the United States for any population, pregnant or not. A physician would not prescribe it during pregnancy; any legitimate growth hormone therapy considered medically necessary in pregnancy would use an approved rhGH product under direct monitoring instead.

Sources

1. U.S. Food and Drug Administration, FDA Warning Letters and compounding guidance on peptides: CJC-1295 and similar peptides are sold as research chemicals not approved for human use and outside FDA-approved drug status
2. NIH National Library of Medicine, StatPearls: Growth Hormone: Growth hormone stimulates hepatic IGF-1 production as part of the somatotropic axis
3. Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism, 2006: CJC-1295 pharmacokinetic and half-life data (no-DAC ~30 min, DAC ~6-8 days) from human dosing study in healthy adults
4. FDA, ICH S5(R3) Guidance on Reproductive Toxicology Testing: Standard reproductive and developmental toxicology testing framework expected before pregnancy safety claims for drug candidates
5. FDA, Genotropin (somatropin) Prescribing Information: Genotropin label notes no adequate well-controlled studies in pregnant women and caution recommended during breastfeeding
6. Raun K, et al., European Journal of Endocrinology, 1998: Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release via a distinct receptor pathway from GHRH analogues
7. NIH National Library of Medicine, Growth hormone co-treatment in IVF for poor responders (review): Adjunct recombinant growth hormone is used in some monitored IVF protocols for poor ovarian responders
8. FDA, iPLEDGE Risk Evaluation and Mitigation Strategy for Isotretinoin: Isotretinoin requires a mandatory FDA pregnancy prevention program due to confirmed teratogenicity, contrasted with CJC-1295's unregulated status